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Abstract
The activation of cells that do not express the membrane bound interleukin-6 6 receptor (IL-6R) by IL-6 and the soluble IL-6 receptor
(sIL-6R) is termed transsignalling. Transsignalling may be an pathogenetic factor in human diseases as diverse as multiple myeloma (MM),
Castleman’s disease, prostate carcinoma, Crohn’s disease, systemic sclerosis, Still’s disease, osteoporosis and cardiovascular diseases. IL-6
and sIL-6R may directly or indirectly enhance their own production on endothelial or bone marrow stromal cells. Positive feedback autocrine
loops thus created in affected organs may either cause or maintain disease progression. In autoimmune or vasculitic disease, the ability of the
IL-6/sIL-6R complex to inhibit apoptosis of autoreactive T-cells may be central to the development of tissue specific autoimmunity. The anti-
apoptotic effect of the IL-6/sIL-6R complex may be involved in tumour genesis and resistance to chemotherapy.
Only in rare cases, where counterregulation has failed, there is a notable systemic effect of IL-6/sIL-6R. Appropriate animal models are
necessary to establish the pathogenetic role of the IL-6/sIL-6R complex. A specific treatment option for diseases influenced by the sIL-6R
could be based on gp130–Fc, a soluble gp130 (sgp130) linked to the Fc-fragment of IgG1. gp130–Fc has shown efficacy in vivo in animal
models of Crohn’s disease.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Interleukin-6 (IL-6) exerts diverse effects on a variety of
different organs or cell systems. It plays a central role in the
differentiation and growth of haematopoietic precursor cells,
B-cells, T-cells, keratinocytes, neuronal cells, endothelial
cells, osteoclasts and osteoblasts [1–4]. Moreover, IL-6
induces the hepatic acute phase response by modulating the
transcription of several liver-specific genes during inflam-
matory states [5]. Altered levels of IL-6 have been found in an
astonishing variety of different diseases including multiple
myeloma (MM) [6], Castleman’s disease [7–9], Crohn’s
disease [10], mesangial glomerulonephritis [11], osteopo-
rosis [12,13], cardiac ischaemia[14], cachexia [15], rheuma-
toid arthritis (RA) [16–18], sepsis [19,20] and AIDS [21].
Effective ways to block the biological activity of these cyto-
kines would thus promise considerable therapeutic potential
[22,23].
The diversity of IL-6 driven biological effects is all the
more surprising, since the IL-6 receptor (IL-6R) is only
present on a comparatively small number of cells, i.e.
hepatocytes, monocytes, neutrophils, and some T- and B-
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cells, whereas gp130 is expressed by all body cells [24].
However, a soluble form of the IL-6 receptor can be formed
either by alternative splicing [25–28] or by shedding of the
membrane bound IL-6R [29–31]. Recent evidence indicates
that the pathophysiological effects of IL-6 may depend
strongly on a soluble form of the receptor. This article will
review new data concerning the pathophysiological effects
of the soluble IL-6 receptor (sIL-6R) in human diseases and
in animal models of human diseases.
2. Characteristics of signalling via IL-6/sIL-6R
2.1. Transsignalling
Classically, binding of IL-6 to the membrane-bound IL-6
receptor (the a-receptor) causes recruitment of two mem-
brane-spanning gp130molecules (h-receptors) into a tetra- or
hexameric, active IL-6 receptor complex [32]. Neither IL-6
nor IL-6R alone binds or activates gp130, which effectively
means that the heterodimeric complex IL-6/ IL-6R consti-
tutes the ‘‘active cytokine’’, similar to the p35 and p40
subunits of interleukin-12 and interleukin-23 [33,34]. Homo-
dimerisation of the two gp130 molecules causes phosphor-
ylation of gp130 and the transcription factors STAT1 and
STAT3 by Janus-Kinases (JAK1, JAK2, TYK2), which are
constitutively associated with gp130 [35]. STAT3-dependent
gene expression also causes upregulation of inhibitory pro-
teins of the suppressor of cytokine signalling (SOCS) family
that interfere with JAK activity [36–38]. In addition, phos-
phorylation of gp130 also triggers the ras/MAP-kinase path-
way via adaptor proteins, leading to activation of the
transcription factors NF-IL-6 and AP-1 [35].
Importantly, the IL-6Ra is not involved in signalling. A
soluble form of the IL-6R (sIL-6R) is still able to bind IL-6
and the complex of IL-6 and the sIL-6R activates target cells
expressing gp130 in a process termed ‘‘transsignalling’’ [39]
(Fig. 1). The IL-6/sIL-6R complex may therefore either
potentiate the IL-6 activity on cells expressing the trans-
membrane IL-6R [24,40,41] or widen the array of potential
IL-6 targets to cells devoid of the transmembrane IL-6R.
The sIL-6R may also protect IL-6 against proteolytic
degradation at sites of inflammation [42]. However, the
activity of the IL-6/sIL-6R complex is limited by the
presence of a soluble form of gp130 (sgp130) in the serum
which competes effectively with membrane bound gp130
for the sIL-6R/IL-6 complex [43]. It was even suggested
that in vivo, the principle function of the sIL-6R is to
antagonize IL-6 by formation of a ternary complex of IL-6,
sIL-6R and soluble gp130 [43]. A more subtle study,
however, demonstrated recently that sgp130 inhibits only
IL-6 effects that are mediated via the sIL-6R, but not those
transmitted via the membrane bound receptor [44]. While
serum concentrations of IL-6 in healthy donors are hardly
detectable or in the low pg/ml (pM) range, they may rise
1000-fold to levels of beyond 5 ng/ml [6], where IL-6
activity in vitro reaches its maximum [45,46]. In contrast,
serum concentrations of sIL-6R and sgp130 show much
smaller differences between health and disease and in most
cases do not rise by more than a factor of 2 [47]. Simple
physico-chemical considerations suggest that even at very
high levels of IL-6 (i.e. 5 ng/ml) more than 98% of the IL-
6sIL-6R complex in the serum exist in the inactive com-
plex with sgp130 (Fig. 2).
The assembly of the IL-6 receptor complex appears to
possess a self-antagonizing capacity in response to surplus
Fig. 1. Transsignalling of the soluble IL-6R. IL-6 classically activates cells by binding to the membrane-bound IL-6R followed by recruitment of two gp130
molecules which activates downstream signal cascades. A soluble form of the IL-6R (sIL-6R) might be generated by proteolytic cleavage by a sheddase that
might be TACE or by alternative splicing. The sIL-6R is agonistically active, so that a complex of IL-6/sIL-6R can activate cells which are normally
unresponsive to IL-6, since they do not express the membrane bound IL-6R. This process is called transsignalling [39].
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IL-6 similar to that observed for insulin[32]. Low concen-
trations of IL-6 and IL-6R are hypothesized to induce active
tetrameric complexes, whereas high concentrations would
transform the tetramer into an inactive hexamer. In addition,
the ratio between IL-6, IL-6R and the number of gp130
molecules on the surface of the target cell will also deter-
mine whether or not a cell will respond to IL-6 [24]. It
therefore appears that IL-6-dependent signalling is set up at
different levels in a way to terminate IL-6-dependent signal-
ling pathways soon after activation and to locally confine its
effects. Where systemic effects of the IL-6.sIL-6R complex
are prominent, these security barriers have broken.
2.2. Insights into in vivo effects of transsignalling via the
IL-6/sIL-6R complex from transgenic mice
Double-transgenic mice have been generated by cross-
breeding mice that express human IL-6 and human sIL-6R
under liver specific promoters [48]. Compared to the single
transgenic mice [48,49], the double-transgenics were much
smaller and displayed a phenotype dominated by a marked
hepatosplenomegaly due to an excessively increased extra-
medullary haematopoiesis (Table 1). Apparently, the IL-6/
sIL-6R complex effectively stimulates haematopoietic pro-
genitor cells. Remarkably, the double transgenic mice also
developed plasmocytoma [50], although the mice did not
possess a Balb/c background, which previously appeared as a
prerequisite for plasmocytoma development [49,51]. Further
analyses of liver pathology in the double-transgenic mice
demonstrated multifocal hepatocellular hyperplasia, haema-
topoietic foci accompanied by significant fibrosis and expres-
sion of acute-phase genes around the periportal region where
the sIL-6R was expressed, consistent with a predominantly
paracrine action of the sIL-6R [48,50]. A change in the
genetic background of the double-transgenics changed this
picture [52]: these mice did not develop plasmocytoma, but
displayed sinusoidal endothelitis and a condition termed
nodular regenerative hyperplasia (NRH) already at 7 weeks
of age, whereas in older mice (4–6 months) hepatic adeno-
mas were observed. In humans, both conditions may have the
potential for malignant transformation [53–55]. NRH
appears to be associated with autoimmune diseases, myelo-
or lymphoproliferative conditions, and glomerulonephritis
Table 1
Effects of overexpression of IL-6 and the sIL-6R in double-transgenic mice
. Hepatomegaly [384]
. Splenomegaly [384]
. Weight loss [384]
. Extreme granulocytosis [384]
. Thromobocytosis [384]
. Acute phase response [48]
. Plasmocytoma [50]
. Nodular regenerative hyperplasia, hepatic adenoma [52]
. Intrahepatic endothelitis [52]
. Astrogliosis [385]
. Blood–brain barrier damage [385]
Fig. 2. Inhibition of transsignalling by soluble forms of gp130. sgp130 and gp130-RAPS are naturally occuring subforms of gp130, whereas gp130–Fc is an
engineered variant [44]. In contrast with sgp130 and gp130–Fc, the short soluble gp130 variant gp130-RAPS might also inhibit signalling via the membrane
bound receptor [127]. An estimation for the prevalence of active IL-6sIL-6R complexes compared to the inactive IL-6sIL-6Rsgp130 is derived from the
following equations: IL-6 + sIL-6RZIL-6sIL-6R (1) and IL-6sIL-6R+ sgp130ZIL-6sIL-6Rsgp130 (2) with KD1=[sIL-6R].[IL-6]/[IL-6sIL-6R] describing
the affinity of IL-6 to the sIL-6R and KD2=[IL-6sIL-6R].[sgp130]/[IL-6sIL-6Rsgp130] the affinity of IL-6sIL-6R to sgp130. The ratio between neutralized
and active IL-6sIL-6R complex is then given by [IL-6sIL-6Rsgp130]/[IL-6sIL-6R]=[sgp130]/KD2. Using average values from several studies of around 80
ng/ml (1.3 nM) for the sIL-6R, 360 ng/ml (3.6 nM) for sgp130 [69], KD1 = 0.5 nM and KD2 = 0.05 nM [43], the ratio between neutralized and active IL-
6sIL-6R complex is estimated to be around 70 and the concentration of the active complex around 1.3 nM. gp130–Fc is a stronger inhibitor of the IL-6sIL-
6R complex than sgp130 [44]; data for gp130-RAPS are not available.
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and is prevalent in about 5% of patients older than 80
[53,56,57]. Conspicuously, increased levels of IL-6 and IL-
6R have been measured under these circumstances.
3. The sIL-6R in systemic diseases: autoimmune and
vasculitic disorders
3.1. Vasculitis
Careful study of autoimmune disorders in standard
medical textbooks (e.g. [58–60] suggest that in many
instances these disorders share a common trait: in most
cases the affected organ displays an infiltrate of mononu-
clear cells and very often vasculitic symptoms may be
observed clinically and pathologically. Infiltrate and vascu-
litis need not necessarily be found in the same location.
Examples for such diseases are Wegener’s granulomatosis,
systemic lupus erythematodes and systemic onset iuvenile
rheumatoid arthritis (IRA).
Endothelial cells do not express the IL-6R, but can be
stimulated by the IL-6/sIL-6R to express monocyte attractant
protein (MCP)-1, MCP-3, IL-8, IL-6, vascular cell adhesion
molecule 1 (VCAM-1), intracellular adhesion molecule 1
(ICAM-1) and protein S, which thus provides the basis for
leucocyte recruitment and adhesion [61,62]. Neutrophils
could be one source of sIL-6R, since the IL-6R can be shed
from their surface and thus lead to activation of endothelial
cells [63], similar to that caused by oncostatin M (OSM) [64].
Factors influencing shedding of the IL-6R receptor from the
cell surface may therefore be vital for an understanding of the
processes underlying many inflammatory and autoimmune
diseases. These factors include C-reactive protein, increased
intracellular Ca2 +-levels as well as several bacterial toxins
[65–68]. Recent evidence showed that IL-8 activates
CXCR1 and induces shedding of the IL-6R from infiltrating
neutrophils [69]. Furthermore, stimulation of gp130 in endo-
thelial cells leads to upregulation of gp130 and leukemia
inhibitory receptor (LIFR) in endothelial cells [70]. Thus, a
positive feedback autocrine loop can be activated by IL-6 and
sIL-6R which leads to expression and secretion of an
‘‘inflammatory cocktail’’ required for the recruitment of
inflammatory cells found in vasculitis and tissues affected
by autoimmune disorders (Fig. 3).
This is illustrated by the development of intrahepatic
endothelitis in double transgenic mice expressing IL-6 and
the sIL-6R under a liver specific promoter [52]. While this
concept argues for a strong proinflammatory role of IL-6/
sIL-6R, recent evidence suggests that IL-6/sIL-6R changes
the pattern of leucocyte recruitment from neutrophils to
monocytes during acute inflammation, thus terminating the
inflammatory reaction [71]. However, in the peritonitis
model used, levels of the sIL-6R dropped after an initial
rise and a prolonged rise of the sIL-6R in inflamed tissues
may conceivably lead to chronic inflammation as concluded
from an animal model of Crohn’s disease [10].
A similar autocrine loop has recently been discovered in
smooth vascular cells, where IL-6/sIL-6R cause upregula-
tion of gp130, secretion of MCP-1 and proliferation of
smooth vascular cells, which is characteristic of chronic
inflammation [72]. The uptake of an enzymatically
degraded low density lipoprotein (LDL) by blood mono-
cytes causes IL-6 secretion and shedding of the IL-6R,
leading to smooth vascular cell proliferation, foam cell
formation and induction of MCP-1 [73–75]. Such events
could be involved in the genesis of atherosclerosis where
inflammatory mechanism receive increasing attention [76,
77] and more specifically in ateriosclerosis obliterans where
IL-6 levels correlate with disease activity [78]. Increased
levels of IL-6 and sIL-6R have also been measured in
patients with hyperthyroid Graves disease [79, 80], an
autoimmune disorder characterised by a typical ophthalm-
Fig. 3. A possible positive feedback loop involving the sIL-6R in vasculitis. Endothelial cells are unresponsive to IL-6, since they do not express the IL-6R.
However, this may be generated by shedding of the IL-6R from neutrophils or macrophages, and can then activate endothelial cells [63,64]. Activated endothelial
cells upregulate gp130 and LIFR [70], and secrete molecules that enhance shedding, induce leucocyte and lymphocyte recruitment as well as adhesion of these
cells [61]. This mechanism could also be involved in the activation and proliferation of smooth muscle cells observed in inflamed arteries [72].
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opathy. The ophthalmopathy results from excessive thicken-
ing of intraocular muscles that is unrelated to thyroid
hormone levels, but in view of the above effects on smooth
muscle cells, a similar effect of the IL-6/sIL-6R complex on
the affected muscles appears not unlikely.
A link might also exist between infections with certain
viruses and vasculitis. Human parvovirus B19 stimulates
expression of IL-6 (but not of tumour necrosis factor a
(TNFa), IL-1h or IL-8) in primary human haematopoetic
and endothelial cells [81], whereas cytomegalovirus induces
IL-6 expression in lung fibroblasts by a NF-nB-dependent,
receptor mediated pathway [82]. Parvovirus B19 infections
are frequently found in arthritis and arteritis [83–85] and
vasculitic phenomena are present in cytomegalovirus infec-
tions. Puumala Hantavirus infections cause haemorrhagic
fever with renal and pulmonary syndrome which is asso-
ciated with high levels of IL-6, IL-1h and TNFa as well as
CRP and nitric oxide levels [86]. Furthermore, paramyxo-
virus infections appear to be related to Paget’s disease and
these viruses induce IL-6 [87], which is important for the
genesis of the bone and vascular pathology of Paget’s
disease (Ref. [22]). In Paget’s disease, increased expression
of the IL-6R was observed [88], but as in the other virus
infections mentioned, no data are available for the sIL-6R.
Considering the pathology of the diseases, one would
predict a role for the sIL-6R.
3.2. The sIL-6R and rheumatoid arthritis
RA comprises mild self-limiting forms as well as multi-
system inflammation with substantial morbidity and mort-
ality [89]. Activation of dendritic cells by different inflam-
matory stimuli was suggested to cause human RA [90]. RA
begins with an inflammation of articular synovia which is
characterized by angiogenesis, leucocyte infiltration, and
cellular hyperplasia and is associated with the expression of
adhesion molecules, proteinases, proteinase inhibitors and
cytokines, among them TNFa, IL-1a and IL-6 [91, 92].
Monocytes and synoviocytes are the major producers of these
cytokines [93]. It is thought that a shift to TH1-cell derived
cytokines is an important factor in disease activity, since RA
improves on application of IL-4, IL-10 or IL-13 in animal
models or in association with a TH2-cell dominated immune
status (pregnancy, HIV-infection) [94]. Synovial inflamma-
tion results in a hyperplasia consisting of macrophage (type
A) and the fibroblast-like (type B) and a striking infiltration of
mononuclear cells (T-, B-, plasma cells, macrophages) into
the sublining of the inflamed synovium [91]. The inflamed
synovium evolves into a histologically distinct form, the
pannus, that causes the joint erosions characteristic of RA.
Joint erosion starts with penetration of the pannus into the
cartilage and leads to irreversible tissue destruction by the
action of collagenases (matrix metalloproteinase (MMP)-1,
MMP-8, MMP-13) [95,96].
OSM and IL-6 act synergistically with IL-1a to upregu-
late MMP-1 and MMP-13 in bovine and human cartilage
explant cultures [95,96]. The OSM effect is mediated by the
specific OSM receptor, while the IL-6 effect depends on the
presence of the sIL-6R. Participation of IL-6 and the sIL-6R
in cartilage collagen breakdown, a key event in the joint
destruction of RA, could explain the positive correlation of
serum IL-6 levels with RA activity [97–99]. The described
findings could also explain the survival promoting and
stimulating effect on B-cells of bone marrow and synovium
cells from RA patients [100]. However, it was also reported
that the IL-6/sIL-6R complex induces upregulation of the
cartilage protective proteinase inhibitor, tissue inhibitor of
metalloproteinases (TIMP)-1 [101] and inhibits proliferation
of fibroblastic synovial cells [102], whereas reduced carti-
lage and bone destruction were reported in IL-6 / mice
[103,104].
Other experiments in IL-6 / mice have shown that IL-
6 is essential for the development of collagen- or antigen-
induced arthritis [105,106]. An impaired immune response
has been described in such mice [107]. However, IL-6
deficiency did not prevent arthritis in TNFa-transgenic mice
[105], although TNFa induces expression of IL-6
[108,109]. Whereas anti-TNFa was successfully introduced
into the clinic either as a partly humanized mouse mono-
clonal antibody against TNFa or as a fusion protein of
soluble TNFa receptor (TNFR) and the Fc-fragment of
human IgG1 (etanercept) [91,110–112], treatment with
neutralizing anti-IL-6 antibodies had to be discontinued
for pharmacodynamic reasons despite promising results
[113]. Several other drugs with known anti-rheumatic activ-
ities, including FK506, decrease levels of IL-6 [114–117].
At levels used for the treatment of IRA, aspirin inhibits InB
kinase, an upstream activator of NF-nB [118] that in turn
induces IL-6 expression [119].
Antibodies against murine IL-6R achieved symptomatic
improvement when given at an early stage of murine colla-
gen-induced arthritis [120], whereas an anti-human IL-6R
antibody exerted an anti-inflammatory effect on human RA
tissue implants in the SCID mouse model [121]. In cyno-
molgous monkeys, a humanized anti-IL-6R antibody inhibits
the development of collagen induced arthritis [122–124].
These results stimulated the development of new therapeutic
strategies in human RA based on neutralizing antibodies
against the IL-6R that are now in clinical trials [125,126].
The importance of signalling via the IL-6 receptor in RA is
further indicated by the recent finding that a new soluble, 50-
kDa form of gp130, gp130-RAPS, is an autoantigen found in
the serum and synovial fluid of RA patients [127]. gp130-
RAPS is generated by alternative splicing, lacks the fibro-
nectin-type III like (FNIII) domains of gp130 and carries a
unique sequence, NIASF, at the COOH-terminus of the
cytokine binding module. Expression of gp130-RAPS is
upregulated by the IL-6/sIL-6R complex, OSM and leukae-
mia inhibitory factor (LIF) on synovial cells. In contrast to
soluble forms of gp130 that include the COOH-terminal
FNIII domains, gp130-RAPS appears to inhibit IL-6 signal-
ling also via the membrane bound receptor. The NIASF
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epitope is recognized by an autoantibody that neutralizes the
inhibitory effect of gp130-RAPS on IL-6 signalling. The
presence in the serum of the autoantibody was a highly
sensitive and specific marker for RA and correlated with
CRP-levels and erythrocyte sedimentation rates in RA.
Although the available data thus indicate a crucial role for
the IL-6R in RA, it is presently unclear whether this implies
signalling via the membrane bound or the sIL-6R or both.
Due to its specific inhibition of the sIL-6R, gp130–Fc would
be an appropriate means to answer this question.
3.3. IRA (Still’s disease): an sIL-6R-dependent disease
Clinical symptoms of IRA read like a list of IL-6 induced
symptoms (Table 2). Indeed, increased levels of IL-6 and
the sIL-6 receptor have been found in IRA [18,128] and in
particular, total sIL-6R levels as well as IL-6 levels correlate
with disease activity and subside during remission [128–
130]. A polymorphism (G/C) exists at position  174 in the
5V-flanking region of the IL-6 gene. Associated with lower
IL-6 levels,  174C is found less frequently in patients with
IRA and thus seems to protect against the disease [131]. In
one study, IL-6 and sIL-6R levels were inversely correlated
[18], but the enigma was readily resolved by the detection of
IL-6/sIL-6R complexes which contained levels of complex
bound IL-6 20-fold higher than free levels measured by
biological assays. Soluble gp130 levels were not measured
in this study, however, the inactivity of the IL-6/sIL-6R
complexes suggests that they were complexed with sgp130.
Furthermore, the relation between free and complexed IL-6
in this study is very much in line with the calculation above
(see legend to Fig. 2). Biological assays proved insufficient
to determine total serum levels of IL-6, but combination
with suitable ELISA measurement allowed to differentiate
between IL-6, sIL-6 and IL-6/sIL-6R complexes.
Mononuclear cells from synovial fluid of patients with
IRA were predominantly TH1-cells [132], in line with the
higher levels of IL-12 in patients with active disease [133].
Serum levels of IL-8 and MCP-1 are increased in active
IRA, and synovial leucocyte counts as well as synovial fluid
levels of IL-8 and MCP-1 correlate with IL-6 levels [134].
Systemic onset IRA is a prime example of a disease
controlled by IL-6 and sIL-6R levels and one would predict
that gp130–Fc would be of therapeutic value in this disease.
In addition, a recent study concluded that reduced IL-10
production is of pathogenetic significance in IRA and found
increased levels of soluble IL-1 receptor antagonist (IL-
1RA) and of soluble TNFRI and II [135]. Anti-TNFa
therapy with etanercept clearly improved the clinical out-
come in a phase III study of patients responding inad-
equately to conventional therapy [136].
3.4. Systemic sclerosis (scleroderma)
Fibroblasts from patients with systemic sclerosis (SSc,
scleroderma) secrete high amounts of IL-6 after stimulation
with IL-1h and PDGF [137–139]. Serum levels of IL-6 are
regarded as an indicator of disease activity and correlate with
progressive fibrosis [137,140]. It is thought that IL-6 con-
tributes to the excessive production of extracellular matrix in
systemic sclerosis, which can be inhibited by anti-IL-6
antibodies as measured by procollagen I production [141].
The therapeutic effect of cyclosporin A in SSc may partly
reflect a decrease in IL-6 production [142]. Peripheral blood
mononuclear cells from systemic sclerosis patients release
increased levels of sIL-6R [143]. Since stimulated and un-
stimulated SSc fibroblasts release IL-8 to the same extent as
IL-6, IL-8-induced shedding of the IL-6R may contribute to
the release of sIL-6R by peripheral blood mononuclear cells
[144]. sIL-6R levels correlated significantly with pulmonary
fibrosis, skin thickness and the appearance of autoantibodies
[140,145,146]. The disease-specific anti-topoisomerase I
autoantibody production resulted from T-cell-dependent B-
cell activation that required both MHC/T-cell receptor and
CD40/CD40L interactions in its early phase, while IL-6 was
important in the late phase [147]. Analysis of monozygotic
twins revealed that anti-topoisomerase I antibody response
reflected in vivo activation of topoisomerase I-reactive T
cells derived from the normal T cell repertoire [148]. Bio-
active IL-6-anti-IL-6 autoantibody complexes were detected
in some patients with systemic sclerosis [149].
In localized cutaneous scleroderma, but not systemic
scleroderma, about half of the patients display elevated
sgp130 levels in addition to increased sIL-6R levels [146].
Patients with increased sIL-6R levels are younger at disease
onset, whereas those with increased sgp130 levels are older
[146]. Apparently, elevated sgp130 levels are associated
with the more benign plaque type cutaneous lesions and the
production of IgM anti-histone antibodies, IgM rheuma
factor and increased sIL-6R levels with the more destructive
linear lesions and IgG anti-histone antibodies. Thus, it
appears that the activity of the IL-6/sIL-6R system may be
an important factor in the disease activity of both localized
and systemic sclerosis.
3.5. A role for the sIL-6R in renal disease
Mesangial-proliferative glomerulonephritis is the major
pathology underlying renal diseases such as IgA-nephrop-
athy, Henoch-Scho¨nlein purpura and post-streptococcal glo-
merulonephritis, which represent around 20–40% of all
Table 2
Clinical symptoms of IRA (Still’s disease) [89]
1. High, daily fever spikes
2. Evanescent rash appearing with fever
3. Anaemia
4. Thrombocytosis
5. Leucocytosis
6. Lymphadenopathy
7. Polyserositis
8. Hepatosplenomegaly
9. Weight loss
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glomerulonephritides [58]. Mesangial cells of patients with
IgA-nephropathy or proliferative mesangial glomeruloneph-
ritis constitutively secrete IL-6, and these patients display
increased urinary and serum levels of IL-6 which appear to
correlate with mesangial proliferation and disease activity
[150–153]. Mesangial proliferation is frequently observed in
IL-6 overexpressing mice [154–157] as well as in patients
with IL-6 associated diseases such as Castleman’s disease or
POEMS syndrome (Ref. in [22]). In contrast to these obser-
vations, IL-6 does not induce proliferation of human mesan-
gial cells [158,159]. However, mesangial cells do not express
the IL-6R, but in the presence of the sIL-6R, IL-6 causes
expression and secretion of MCP-1, but not of other proin-
flammatory chemokines (IL-8, Rantes or MIP-1a) by human
mesangial cells in vitro [160]. Bacterial proteins can cause
shedding of the IL-6R from blood mononuclear cells [65,66],
and the sIL-6R thus released can elicit inflammatory
responses on endothelial cells [63]. A similar mechanism
involving transsignalling of IL-6 and the sIL-6R could
contribute to leucocyte recruitment in inflammatory nephro-
pathies. This mechanism provides a rationale to understand
the detection of IL-6 and sIL-6R in renal biopsies of patients
with IgA-nephritis which pathologically presents as mesan-
gioproliferative glomerulonephritis [161].
The importance of signalling via the IL-6R is further
exemplified by the ability of neutralizing anti-IL-6R anti-
bodies to suppress lupus nephritis in lupus-prone NZB/NZW
F1 and MRL-lpr/lpr mice [162,163]. However, in patients
with active systemic lupus erythematosus, the sIL-6R seems
to be inversely related to disease activity [99,164,165]. In
patients with endstage renal disease undergoing hemodialysis
with cuprophan, but not polymethylmethacrylate mem-
branes, increased levels of circulating IL-6R were measured
[166]. The same study also reported increased sIL-6R levels
in uremic patients which makes one speculate whether
increased IL-6 and sIL-6R levels in this group are a factor
in the genesis of atherosclerosis, amyloidosis and weight
reduction frequently found in this group of patients.
3.6. Diabetes mellitus
Increased levels of IL-6/sIL-6R complexes have been
observed in patients with type II diabetes mellitus [167]. IL-
6 levels correlated with the levels of HbA1C, a marker for
long-term glucose concentrations in diabetics, and plasma
fibrinogen, a known risk factor for atherosclerosis. Similar
data are not available for type I diabetes, which in contrast
to type II diabetes is considered as an autoimmune disease.
However, in an animal model of type I diabetes, nonobese
diabetic (NOD) mice, IL-6 production in pancreatic islets
correlated with the development of autoimmune diabetes
[168]. sIL-6R was not determined. Overexpression of IL-6
under a pancreas specific promoter caused an inflammatory
infiltrate consisting of B- and T-lymphocytes. Despite the
insulitis, the animals did not develop hyperglycemia in con-
trast to the NOD mice [169]. It was concluded that IL-6
dependent signalling was not sufficient to trigger a func-
tional autoimmune reaction itself, but rather served to
recruit, maintain and stimulate the cells involved in mount-
ing the autoimmune reaction. The role of the sIL-6R in the
pathogenesis of type I diabetes was not investigated, but in
Crohn’s disease (see next paragraph), the sIL-6R appears to
entertain inflammatory processes causing disease activity.
Conceivably, it exerts a similar function in type I diabetes.
3.7. Crohn’s disease
Crohn’s disease is a discontinuous inflammation of the
gastrointestinal tract with increasing incidence. Recent
results suggest that autoreactive TH1-cells play a pivotal
role in the pathogenesis of the disease [170].The levels of
IL-6 and sIL-6R produced by mononuclear cells from
inflamed mucosa (but not serum levels) correlate positively
with disease activity [171]. T-cells from inflamed mucosa of
patients with Crohn’s disease and a mouse model of
inflammatory bowel disease (IBD) showed reduced expres-
sion of the transmembrane IL-6R, but secreted extremely
high amounts of IL-6 and were virtually resistant to apop-
totic stimuli [10]. Anti-apoptotic genes (bcl-2, bcl-x) were
upregulated in a STAT3-dependent manner. Treatment with
the gp130–Fc fusion protein broke T-cell resistance towards
apoptosis as effectively as a neutralising anti-IL-6R anti-
body, thus demonstrating that the expression of anti-apop-
totic genes depended on signalling via the sIL-6R.
Furthermore, gp130–Fc largely reduced disease-activity
indices in several murine models of colitis as effectively as
anti-TNF treatment, thus proving a pivotal pathogenetic role
of the sIL-6R also in vivo. Combined anti-IL6R and anti-TNF
treatment was only slightly more effective than each treat-
ment alone, suggesting that IL-6 and TNF dependent pro-
cesses overlap in inflammatory bowel disease. Neutralisation
of the (soluble) IL-6R may represent a new therapeutic
approach to the treatment of Crohn ’s disease. Moreover, a
specific anti-sIL-6R drug already exists with the gp130–Fc
protein. gp130–Fc is constructed similar to etanercept the
sTNFR–Fc protein that has been successfully introduced into
therapy of Crohn’s disease and RA in recent years.
3.8. Potential mechanism of IL-6/sIL-6R in autoimmune
disorders
The description of the pivotal role of the sIL-6R in
Crohn’s disease by Atreya et al. [10] is the clearest example
for the pathogenetic importance of the sIL-6R in a human
autoimmune disease. Apparently, the key factor in the active
phase of Crohn’s disease is the resistance of autoreactive
cytotoxic CD8+-T-cells against apoptotic cell death. This is a
consequence of activation of STAT3 by the IL-6/sIL-6R
complex and STAT3-dependent upregulation of anti-apop-
totic genes. In T-cells, an autoregulative STAT3-binding
element exists in the STAT3 promoter, which is crucial for
STAT3 mRNA expression and IL-6 induced anti-apoptotic
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signalling [172]. It is, however, unclear against which antigen
the T-cells in Crohn’s disease are directed nor are the
mechanisms of antigen presentation known. The designer
cytokine Hyper-IL-6, a fusion protein of IL-6 and sIL-6R that
has much higher bioactivity than the combination of IL-6 and
sIL-6R [173,174], can be used for ex vivo expansion of
dendritic cells [175] and IL-6/sIL-6R may well affect den-
dritic cells in vivo. Thus, IL-6 is known to inhibit the Na+/K+-
ATPase [176] and to acidify early endosmosis in dendritic
cells, which cause presentation of cryptic antigens to T-cells
[177]. Patients with RA have a dysfunctional Na+/K+-
ATPase [178]. According to Matzinger’s danger theory
[179,180] naı¨ve T-cells die, if they only receive signal 1
(properly presented antigen) and signal 2 (activation of
CD40) does not follow. The observation by Neurath and
coworkers may suggest that IL-6/sIL-6R provides an unspe-
cific substitute for signal 2. In this case, autoimmune reac-
tions could arise in all tissues where uncontrolled/unlimited
release of IL-6/sIL-6R occurred. Primarily, effects would be
localized to the site of release, since only there sgp130 would
be unable to neutralize IL-6/sIL-6R (see Fig. 2).
This concept might explain the multitude of autoimmune
phenomena observed in diseases where IL-6, sIL-6R or viral
IL-6 is increased (references in Refs. [22,23,47,68]). Thus,
investigation of causes for increased release of sIL-6R in
autoimmune disorders might lead to a better understanding
of the pathogenesis of this group of diseases. The incidence
of autoimmune phenomena is increased in old age [181] and
it is probably no coincidence that the levels of the sIL-6R
produced by shedding of the IL-6R, but not those produced
by alternative splicing, are increased in old age, too [68].
Although this hypothesis needs further testing, a promising
therapeutic gp130–Fc would already be at hand, given the
effect of this agent in animal models [10].
4. The sIL-6R in central nervous diseases
4.1. Multiple sclerosis
Astrocytes are a major source of regulated IL-6 expres-
sion in the central nervous system. The expression of IL-6
can be induced by TNFa, IL-1h and OSM; furthermore, IL-
6 upregulates its own expression in the presence, but not the
absence of the sIL-6R [182]. Experimental autoimmune
encephalitis (EAE), an animal model of multiple sclerosis
(MS), cannot be elicited in IL-6 / mice [183–186]. De-
creased expression of ICAM-1 and VCAM-1 on endothelial
cells in IL-6 / mice was suggested as one reason for this
observation [184]. This would imply that the sIL-6R is
necessary for the genesis of EAE in wild-type animals. In
humans, serum levels of IL-6 were found unaltered in MS
patients, but the levels of sIL-6R as well as sgp130 were
significantly increased and correlated with disease activity
[187]. In contrast to serum levels, sgp130 levels in the
cerebrospinal fluid of patients with MS were decreased,
which would be consistent with diminished inhibition of the
sIL-6R/IL-6 complex in MS patients. However, in a sub-
sequent clinical analysis, no association between IL-6/sIL-
6R levels in serum and cerebrospinal fluid and anti-myelin
antibodies was found [188].
4.2. Alzheimer’s disease (AD)
In addition to MS, evidence for deranged inflammatory
processes in the brain of patients suffering from AD has been
gathered in recent years. Thus, expression of h-amyloid
precursor protein (h-APP) is strongly increased by the
complex of sIL-6R and IL-6 [189] and in the cerebral plaques
of AD patients, the presence of IL-6 appears to correlate with
clinically detectable dementia [190]. IL-6 was also found in
the diffuse plaques of AD patients which are thought to
precede the neuritic changes associated with dementia in AD
[191]. Although the  174 C-allele polymorphism of the IL-
6 gene was associated with a delayed onset of AD in a clinical
study on AD patients [192] (Table 3), serum and cerebrospi-
nal fluid levels of sIL-6R were decreased in two studies
[193,194]. Nevertheless, low sgp130 levels in the CSF of AD
patients contributed to the set of parameters that served as
positive predictors for AD [195].
4.3. Psychiatric disorders
Compared to healthy volunteers, significantly higher
plasma concentrations of IL-6 and sIL-6R were found in
psychotic disorders [196]. IL-6 was significantly higher in
schizophrenic patients, while plasma sIL-6R and sIL-2R
were significantly higher in mania than in normal controls.
In schizophrenic patients, plasma levels of IL-6 and sIL-6R
decreased after neuroleptic treatment compared to pretreat-
ment values. Elevated IL-6 levels in severe depression are
related to hyperactivity of the hypothalamic-pituitary-adre-
nal (HPA) axis [197]. In patients with post-traumatic stress
disorder (PTSD), serum IL-6 and sIL-6R, but not sgp130 or
soluble IL-1RA, were significantly higher than in normal
volunteers. In particular, elevated serum sIL-6R was sig-
nificantly higher in PTSD patients with concurrent major
depression than those without major depression or healthy
controls [198]. One possible explanation for this observation
might be an involvement of the IL-6/sIL-6R in the catecho-
laminergic modulation of anxiety reactions via the HPA. It
Table 3
Involvement of the  174G/C polymorphism in human diseases
. Still’s disease C-allele associated with
lower IL-6 levels,
less severe disease activity
[131]
. Coronary heart disease risk increased in carriers
of the G-allele
[245]
. Kaposi sarcoma Increased incidence in
HIV-positive G-allele carrier
[350]
. Alzheimer’s disease C-allele associated with
delayed onset
[192]
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has been recently demonstrated that the IL-6 type cytokine
ciliary neurotrophic factor (CNTF) reduces body-weight by
the induction of leptin-like pathways in the hypothalamus,
and in IL-6 / mice, a distorted hypothalamic regulation
appears to cause the mature-onset obesity of IL-6 / mice
[199,200]. On the other hand, in anorexia nervosa, serum
sIL-6R levels were decreased, while those of IL-6 as well as
TNFa, TNFRI and -II and IL-1RA were unchanged [201].
5. Cardiac diseases
5.1. Inflammatory processes in heart disease
The role of inflammatory mediators in heart failure,
mainly TNFa, IL-1h and IL-6, has attracted much attention
recently [202–204]. Bowel oedema is frequent in advanced
heart failure and is thought to cause transfer of bacteria or
bacterial toxins across the bowel wall with subsequent
strong activation of inflammatory cytokines [202]. In par-
ticular, TNFa is considered to exert a negative inotropic
effect on the failing heart via its p55 receptor (TNFR1)
[205,206]. Ongoing clinical studies examine the potential of
anti-TNFa therapy in congestive heart failure with etaner-
cept [205,207].
Mice overexpressing IL-6 and membrane-bound IL-6R
(driven by an actin-promoter) develop cardiac hypertrophy
[208]. Cardiac hypertrophy is physiological in well trained
humans, but can become pathological in arterial hyper-
tension, aortic stenosis or heart failure. Surgically induced
pressure overload causes cardiac hypertrophy in wild-type
mice, but not in mice expressing a dominant negative gp130
mutant in the heart [209]. Depending on the genetic back-
ground, conventional gp130 / mice die in utero or shortly
after birth from severe anaemia and hypoplastic ventricular
development [210,211] and conditional knock-out of gp130
immediately after birth results in cardiac abnormalities
[212]. In contrast, cardiospecific gp130 / mice develop
normally without cardiac phenotype. However, a surgically
increased cardiac afterload causes them to die, apparently
due to an increased apoptosis of cardiac myocytes that
correlates with reduced STAT3 phosphorylation[213]. Thus,
direct cardiac gp130 stimulation is dispensable for normal
cardiac development, but appears to relay an anti-apoptotic
effect essential for the survival of cardiac myocytes under
stress and may cause the cardiac hypertrophy observed in
heart failure [208,214].
Cardiomyocytes of patients with irreversible congestive
cardiomyopathy show a 200-fold increased rate of apoptosis
[215]. In patients with severe heart failure, elevated serum
levels of IL-6, sIL-6R and soluble gp130 (sgp130) were
measured [216–218], while the levels of sgp130 correlated
best with impaired haemodynamic status [216]. This would
be consistent with an impaired anti-apoptotic stimulus
mediated via the sIL-6R, but bioactivity of IL-6 in patient
serum samples was increased [216]. IL-6 has been reported
to exert a negative inotropic effect on cardiocytes [219,220]
and to interfere with myocyte remodelling during heart
failure [202,221]. Furthermore, increased levels of the IL-
6 type cytokines cardiotrophin-1 (CT-1) and LIF in human
dilated cardiomyopathy correlated with the severity of
chronic heart failure and left ventricular mass [222,223].
Animal models of viral myocarditis exemplify that IL-6 is a
double-edged sword in heart failure: short-term application
of recombinant IL-6 increased survival and decreased myo-
cardial injury in mice after infection with encephalom-
yocarditis virus [224], whereas transgenic mice that
permanently overexpressed IL-6 displayed a much aggra-
vated viral myocarditis and cardiac insufficiency [225]. IL-6
expression in the heart is upregulated by TNFa and IL-1h,
but IL-6 can then inhibit expression of its inducers during
endotoxic stress [220]. A recent animal study found a
dramatic age-associated increase of LPS-induced IL-6 pro-
duction in cardiac vascular endothelial and smooth muscle
cells, whereas IL-1h and TNFa levels were much less
effected [226]. The prolonged upregulation of IL-6 was
accompanied by increased ICAM-1 expression on endothe-
lial cells indicating the influence of the sIL-6R.
Angiotensinogen II induces IL-6 expression in a MAP-
kinase-dependent manner on cardiac fibroblasts [227]. In
addition, this autocrine/paracrine secretion of IL-6, LIF and
CT-1 mediates angiotensiogen-II-induced cardiac hypertro-
phy in rodent cardiomyocytes [228,229]. The erk1/2 cascade
appears to be particularly important in gp130-dependent
cardiac hypertrophy [230]. Conceivably, the anti-hypertro-
phic effects of angiotensin converting enzyme (ACE) inhib-
itors and angiotensin receptor II antagonists, two classes of
drugs indispensable in the treatment of cardiac failure, may
therefore partially result from an indirect inhibitory effect on
the expression of IL-6 type cytokines. High dose therapy of
the ACE-inhibitor, enalapril, decreased IL-6 bioactivity and
interventricular septal thickness, but increased serum levels
of the sIL-6R, whereas the levels of TNFa and its receptors
remained unchanged [231]. An effect of anti-angiotensino-
gen medication on detrimental effects mediated by IL-6/sIL-
6R or other cytokines of this family might explain why the
beneficial effect of these drugs in cardiac failure vastly
exceeds the effect expected from their blood pressure low-
ering capacity [232]. Interestingly, anti-TNFa therapy with
eternacept caused resolution of heart failure due to giant cell
myocarditis in a patient with Crohn’s disease [233], a
situation where increased activity of the IL-6/sIL-6R system
seems very likely [10,234].
5.2. Cardiac ischaemia
In models of cardiac reperfusion injury, a rapid and
sustained production of IL-6, IL-6R and gp130 was found
[235–238]. Levels of the sIL-6R were not analysed.
Increased IL-6 expression, however, was followed by endo-
thelial ICAM-1 upregulation and transendothelial neutrophil
migration, which are a basis of the neutrophil-mediated re-
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perfusion injury in ischemic myocardium [235,237,239]. An
increased level of the sIL-6R in ischaemic hearts would
explain the upregulation of ICAM-1 in response to IL-6 by
endothelial cells (which are devoid of the IL-6R), but has
not been directly assessed so far. Virtually the same path-
ophysiology as in ischaemic heart disease is active during
splanchnic ischaemia [240,241]. In particular, the reperfu-
sion injury is smaller in IL-6 / mice which underlines the
potential therapeutic benefit of IL-6 antagonists in ischae-
mic situations [242]. In humans, increased IL-6 and
decreased sIL-6R levels were found in acute myocardial
infarction [243] and it was speculated that the decrease in
sIL-6R resulted from increased endocytosis of the IL-6/sIL-
6R complex after binding to gp130 on the plasma mem-
brane. However, another study found increased levels of
circulating IL-6 and sIL-6R in patients with myocardial
infarction [244]. A role of IL-6 in coronary heart disease is
further stressed by the observation that men carrying the IL-
6  174G polymorphism of the IL-6 promoter develop a
higher risk of coronary heart disease [245] (Table 3).
Although, the available evidence not only points to a role
of the sIL-6R not only in congestive heart failure, but also in
ischaemic disease, this speculation requires further study.
6. The sIL-6R and liver diseases
Double transgenic mice expressing IL-6 and sIL-6R
under a liver specific promoter develop hepatocellular hyper-
plasia and hepatocellular adenomas [50,52]. In humans, the
latter condition may be a precancerosis that is followed by
the development of hepatocellular carcinoma (HCC) [55].
Worldwide, the commenest causes of HCC are chronic
infections with Hepatits C and B virus. As in chronic
hepatitis by other causes, the chronic inflammation of the
liver caused by these viruses first leads to liver cirrhosis and
ultimately to HCC. Liver cirrhosis is associated with
increased hepatic expression of IL-2, IL-6 and IL-8 [246].
In chronic hepatitis B virus (HBV) infection, the hepatitis B
virus X-protein upregulates IL-6 expression by a mechanism
involving NF-nB [247]. IL-6 induces release of CRP and
other acute phase proteins by the liver. The highest IL-6
levels were found in liver cirrhosis associated with HCC
[247]. IL-6 was shown to induce expression of hepatocyte
growth factor-like protein which is highly expressed in
HCCs [248]. Both IL-6 and hepatocyte growth factor/scattor
factor signal through STAT3 [249]. Transfection of IL-6 into
non-metastatic HCC cells causes metastasis of these cells
[250]. It has recently been shown that the sIL-6R increases
the responses to supramaximal, but not submaximal IL-6
concentrations [251]. Shedding of the membrane IL-6R from
infiltrating mononuclear or from Kupfer-cells by CRP could
be a source of the sIL-6R in chronic hepatitis [67]. Thus,
continuous stimulation of gp130 and the oncogene STAT3
by IL-6/sIL-6R might be involved in the malignant trans-
formation of hepatocytes.
Recent evidence suggests that the resistance to interferon
treatment in hepatitis C virus infections results from upre-
gulation of IL-8 and inhibition of PKR activity by the
nonstructural virus protein NS5A [252,253]. NS5A also
induces oxidative stress, increases intracellular calcium
levels and activates STAT3 [254]. Increased intracellular
calcium levels can trigger shedding of the IL-6R [255] and
IL-8 has been reported to trigger shedding of the IL-6R from
polymorphonuclear cells by activation of the chemokine
receptor CXCR1 [69]. Recently, increased carotid artery
intima thickness, a parameter to quantify atherosclerotic
changes, was found in patients chronically infected with
hepatitis C virus [77]. The anti-apoptotic effect of active
STAT3 may explain the resistance to interferon treatment
and in the long-run also the carcinogenic effect of chronic
viral hepatitis. The presence of the sIL-6R in the inflamed
liver widens the array of IL-6 responsive cells and may also
participate in the fibrosis that causes cirrhosis.
While chronic activation of STAT3 signalling is onco-
genic, it appears to be important for hepatic regeneration after
acute liver damage. In rats, partial hepatectomy strongly
increases serum concentrations of IL-6 after 12 h and con-
centrations of the sIL-6R after 24 h [256]. Although the role
of the sIL-6R in hepatic regeneration still awaits experimental
confirmation, recent results with Hyper-IL-6 strongly point
into this direction. In mice, peritoneal injection of Hyper-IL-6
after hemihepatectomy shortened the time for complete
regeneration by 2 days compared to IL-6 [257]. Hepatocytes
of Hyper-IL6-treated mice showed an increased rate of
proliferation. In a rat model of acute toxic hepatitis, D-
galactosamine injection causes lethal liver toxicity charac-
terized by increased hepatocyte apoptosis, whereas submax-
imal doses caused hepatitis with decreased liver function
[258]. Application of Hyper-IL-6 several hours after injection
of D-galactosamine prevented death of the toxified animals or
at sublethal doses of D-galactosamine accelerated the restora-
tion of liver function. One may therefore hypothesise that
elevation of IL-6 and sIL-6R are natural defense mechanisms
of the liver that are amplified by the more active designer
cytokine Hyper-IL-6. The sIL-6R may also be involved in the
elimination of hepatitis B virus after IFN-a therapy, since
successfully treated patients display a significant rise of sIL-
6R levels [259]. However, the mechanism of this is not
known at present.
7. IL-6 dependent bone pathology
7.1. Osteoclast activation by the sIL-6R
Although IL-6 type cytokines are not essential for bone
formation [211], signs of bone pathology often occur in IL-
6 associated diseases (Table 4). IL-6 type cytokines enhance
osteoclastogenesis in vitro and in vivo [260–263] by the
induction of receptor activator of NF-nB ligand (RANKL)
expression in stromal/osteoblastic cells [264,265]. Together
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with macrophage stimulating factor (MCSF), RANKL is
necessary and sufficient for osteoclastogenesis from hae-
matopoietic precursors [266]. Stromal/osteblastic cells do
not normally express the IL-6R, but can be stimulated by
OSM or the IL-6/sIL-6R complex [267,268]. It has been
shown that the sIL-6R triggers osteoclast formation by
interleukin 6 and that a neutralizing anti-IL-6R antibody
blocks this effect [269].
The IL-6/sIL-6R system may act downstream of para-
thyroid hormone (PTH), the main hormone regulating Ca2 +-
release from bone substance. PTH induces upregulation of
IL-6 and LIF in osteoblasts by a cAMP-dependent mecha-
nism [270] and PTH induced osteoclast activation can be
blocked by anti-IL-6 antibodies [271].Modest concentrations
of IL-6 were also sufficient to substantially enhance hyper-
calcaemia and bone resorption caused by parathyroid-related
hormone [272]. Iuvenile periodontitis is a disorder associated
with rapid destruction of alveolar bone that causes complete
loss of teeth in adolescence or early adulthood [273]. A 2-kDa
bacterial peptide from Actinobacillus actinomycetemcomi-
tanswas recently isolated from patient material which caused
a pronounced increase of IL-6 production in gingival fibro-
blasts that could not be blocked by antibodies against IL-1 or
TNFa [274]. High levels of sIL-6R have been found in
inflamed gingiva of patients with periodontitis and very likely
contribute to the detachment of gingival fibroblasts and
increased osteoclast activity [275,276]. Interestingly, a link
between periodontitis and increased rate of coronary heart
and cerebrovascular disease is discussed presently, since
periodontal pathogens were found in atheromatous plaques
[273,277–279]. In view of the apparent role of the IL-6/sIL-
6R system in periodontitis, it is conceivable that the IL-6/sIL-
6R system could represent the link between the above
mentioned disorders. Incidentally, an infection with A. acti-
nomycetemcomitans was recently identified as the cause of
temporal arteritis in a patient (personal communication, Dr. J
Faust, I. Med. Klinik, University of Mainz).
7.2. Osteoporosis
Osteoporosis is a consequence of decreased serum sex
steroid levels after ovariectomy, orchiectomy or after meno-
pause. Involvement of IL-6 type cytokines was initially
suggested by the observation that IL-6 /mice are protected
from osteoporosis after ovariectomy [280]. More recent
evidence suggests that estrogens may also modulate osteo-
clastogenesis in the menstrual cycle by effects on the levels of
sIL-6R and IL-6 [281,282]. Sex steroids inhibit IL-6 produc-
tion by stromal/osteblastic cells [283], possibly by blocking
the NF-nB binding site of the IL-6 promoter [284,285]. Sex
steroids downregulate expression of IL-6R and gp130 in
murine bone marrow in contrast to parathyroid hormone that
upregulates gp130 mRNA [286]. Moreover, 17-h estradiol
inhibits phorbol ester-induced shedding of the IL-6R from
osteoblasts in vitro and, importantly, it was shown that
estrogens inhibit shedding of the IL-6R and rise of sIL-6R
serum levels in ovarectomised women [287]. There is also
evidence indicating that estradiol interferes with STAT3
DNA binding by a mechanism involving protein inhibitor
of activated STAT3 (PIAS3) [288]. Shedding of the IL-6R
from osteoblasts may also explain why IL-6, but not IL-11, is
able to sustain the resorptive activity of mature osteoclasts at
high calcium levels [289]. In a clinical study, hormone
replacement therapy in perimenopausal women suppressed
serum levels of the sIL-6R (but increased levels of the IL-
1RA) and there was a positive correlation between changes in
sIL-6R levels and bone loss [290]. A similar correlation
between levels of IL-6 and sIL-6R in bone marrow plasma
was recently found in MM [291]. Upregulation of the IL-6R
was also observed after glucocorticoid treatment of stromal/
osteoblastic cells [267,286]. Since dexamethasone has been
shown to induce shedding of the IL-6R in cells, the bone loss
associated with glucocorticoid treatment might reflect acti-
vation of osteoclasts by the IL-6/sIL-6R complex. Specific
inhibition of sIL-6R could therefore alleviate one of the most
dreaded side effects of long-term glucocorticoid treatment in
addition to its anti-inflammatory role.
8. IL-6 in endometriosis
Endometriosis is the dystopic growth of endometrial cells
at sites outside the uterus. IL-6 alone or in combination with
the sIL-6R inhibits the growth of stromal cell isolated from
secretory, but not proliferative endometrium [292]. The re-
sponsiveness of normal endometrium to IL-6 is regulated by
progesterone and estradiol. In contrast to normal endome-
trium, stromal cells from active endometriosis patients are
resistant to growth inhibition by IL-6. The severity of endo-
metriosis correlates with increased peritoneal fluid levels of
IL-6 [293–295], whereas decreased sIL-6R levelswere found
in the peritoneal fluid of affectedwomen [293]. A relationship
of this phenomenon to the endometriosis-associated infer-
tility and the pathogenesis of endometriosis is discussed.
9. The IL-6/sIL-6R in tumour diseases
9.1. Multiple myeloma (MM)
Several lines of evidence suggest that IL-6 is a key factor
in the pathogenesis ofMM. IL-6 was identified as a factor that
Table 4
Diseases with bone pathology due to IL-6-dependent increased osteoclast
activity where involvement of the sIL-6R appears very likely
. Osteoporosis due to estrogen, androgen deficiency [281,282,287]
. Paget’s disease [87,88]
. Joint destruction in rheumatoid arthritis [96]
. Gorham–Stout disease [386]
. McCune–Albright syndrome [387]
. Hyperthyroidism due to Graves disease [79,80]
. Hyperparathyroidism [270–272]
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induces B-cells to produce immunoglobulin [296]. More
recently, IL-6 was shown to be an essential survival factor
for highly proliferating CD138 human plasmablasts that
controls differentiation of these cells into CD138+, immuno-
globulin-producing plasma cells [297]. IL-6 transgenic mice
on a Balb/c background develop plasmocytosis and plasmo-
cytomas with a t(12;15) translocation [155,298]. Conversely,
IL-6 / Balb/c mice do not develop pristane-oil induced
plasmocytomas [51].Mice that are double-transgenic for IL-6
and sIL-6R also developed plasmocytomas [50], even though
they were in a predominantly C57/BL6 background.
IL-6 is not produced by MM cells, but by bone marrow
stromal cells which are stimulated by MM cells to produce
high levels of IL-6 [299,300]. High levels of sIL-6R have
been found in the serum of MM patients [301], and although
most myeloma cells express detectable levels of IL-6R on
the cell surface, the sIL-6R sensitizes MM cells to stimula-
tion by IL-6 [302]. In vitro, depletion of the sIL-6R caused
largely inhibited proliferation of MM cells [302,303]. sIL-
6R levels correlate negatively with disease progression and
high levels indicate a poor prognosis [304,305]. The prog-
nostic value of sIL-6R levels may reflect the capacity of IL-
6 to upregulate its receptor on MM cells [306]. MM cells
produce the sIL-6R, both by alternative splicing and by
shedding from the plasma membrane [307]. Shedding on
MM cells appears to be (partly) regulated by PKC isoen-
zymes y and D [308]. Apparently, TNFa converting enzyme
(TACE), a membrane metalloproteinase also responsible for
shedding of TNFa and NOTCH [309], is involved in shed-
ding of the IL-6R [310].
IL-6 inhibits apoptosis of myeloma cells and causes
chemotherapy resistance of myeloma cells [311–313]. The
anti-apoptotic effect is due to activation of STAT3 and up-
regulation of bcl-xL and mcl-1, two members of the bcl-2
family [314–316]. Bcl-xL is thought to contribute to the
chemotherapy resistance of myeloma cells and is also
upregulated in the murine B9 MM cell line [313]. Inhibition
of the JAK/STAT-pathway in myeloma cells causes apop-
tosis [314,315] and a specific IL-6 antagonist, SANT7,
renders MM cells more sensitive to treatment with dexame-
thasone and all-trans retinoic acid [317].
In line with the negative correlation of sIL-6R levels and
progression of MM, the IL-6/sIL-6R was shown to upregu-
late bcl-xL and mcl-1 more potently than IL-6 alone [314].
While these data suggest a key role of STAT3 and STAT3-
induced genes in resistance to apoptosis of myeloma cells,
activation of the ras-MAP kinase pathway has also been
reported as a mechanism by which IL-6 protects myeloma
cells from dexamethasone induced apoptosis [318].
The importance of the interaction between bone marrow
stromal cells and myeloma cells for myeloma cell survival is
increasingly recognized [319]. As mentioned above, mye-
loma cells produce sIL-6R and it was recently shown that
sIL-6R enhances IL-6 synthesis by bone marrow stromal
cells [320]. Thus, another positive feedback loop dependent
on paracrine IL-6 and autocrine sIL-6R production may
exist in the bone marrow of MM patients (Fig. 4). This loop
leading to increased prevalence of the IL-6/sIL-6R would
not just reinforce the growth or survival stimulus for
myeloma cells, but may also explain the bone destructions
that are a hallmark of MM by stimulating osteoclast activity
(see below). Furthermore, IL-6 has previously been shown
to upregulate VEGF [321] and this effect might contribute
to the angiogenesis that is observed in bone marrow
infiltrates of myeloma cells and that parallels disease activ-
ity [322,323]. Noteworthy, VEGF also induces expression
Fig. 4. IL-6 and the sIL-6R in the interaction between multiple myeloma and bone marrow stromal cells. Binding of multiple myeloma cells to bone marrow
stromal cells (BMC) leads to IL-6 secretion by BMCs. IL-6 upregulates anti-apoptotic genes in multiple myeloma cells as well as shedding or secretion of the
sIL-6R. The IL-6sIL-6R complex stimulates secretion of metalloproteinases and VEGF by BMCs and may activate osteoclasts. These effects could be
involved in the angiogenesis, osteolytic lesions and chemoresistance frequently observed in patients with multiple myeloma.
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of IL-6 in bone marrow stromal cells [323]. Production of
MMP-1 and MMP-2 by bone marrow stromal cells in
response to stimulation by IL-6/sIL-6R might contribute to
bone resorption, tumour spreading and angiogenesis [269,
320,324–327].
In chronic lymphocytic leukaemia (CLL), B-cell non-
Hogkin lymphoma and monoclonal gammopathy, elevated
levels of sIL-6R were found. sIL-6R levels correlated with
tumour stage, pointing to a potential link to tumour mass
[328]. Although acute myeloblastic leukaemia (AML) blast
cells produce sIL-6R by alternative splicing [329] as well as
signal transducers and activators of transcription proteins
[330], there was no evidence for increased serum levels of
the sIL-6R in AML patients. This stands in contrast to a
control group of MM patients [331]. In Hodgkin’s disease
(HD) cell lines, expression of IL-6 and the IL-6R has been
documented and in one report IL-6 levels paralleled disease
activity in untreated patients [332–334]. However, STAT3
is constitutively activated in these cells and additional
stimulation with IL-6/sIL-6R did not enhance activation
[335].
9.2. Infections with human herpesvirus-8 (HHV-8)
Infection with HHV-8 (also known as Kaposi-sarcoma
associated herpesvirus, KSHV) in immunocompromised
hosts such as HIV-positive patients greatly increases the
incidence of Kaposi’s-sarcoma (KS), a tumour of unclear
clonal origin with endothelial and spindle cell, and the
lymphomatous neoplasms primary effusion lymphoma
(PEL) and multicentric Castleman’s disease (MCD) [336–
339]. HHV-8 encodes a viral interleukin-6 (vIL-6) [340,341]
that activates gp130 directly [70] and promotes haematopoi-
esis, plasmocytosis and angiogenesis [342]. The expression
of vIL-6 in lesions of PEL, MCD and in KS lesions suggests
a causal role of vIL-6 in these diseases[343–346]. Injection
of viral IL-6-expressing NIH3T3 fibroblasts into mice
increases haematopoiesis, plasmocytosis and hypergamma-
globulinaemia, and like human IL-6, vIL-6 causes increased
vascularization of tumours by expression of VEGF [321,
342,347]. However, in KS the IL-6 and sIL-6R complex (but
not IL-6 alone) is a potent growth stimulus for KS spindle
cells that can be neutralized by sgp130 [348,349]. Moreover,
the  174G/C promoter polymorphism of the human IL-6
gene is associated with an increased incidence of KS in HIV-
positive men that are homozygous for  174G [350] (Table
3). In PEL, anti-sense oligonucleotides against IL-6, but not
vIL-6, inhibited growth of tumour cells, and in MCD, a
neutralising anti-IL-6 antibody improved clinical symptoms
[351]. A similar improvement was recently shown with a
humanized neutralizing anti-IL-6R antibody [125]. In con-
trast to KS, however, there is no information on the role of
the sIL-6R in PEL or MCD, and it is unclear whether the sIL-
6R increases the reactivity of tumour cells similar to the
situation in MM. However, in POEMS-syndrome (a plasma
cell dyscrasia often associated with MCD [345]), high IL-6
and low sIL-6R are observed, which normalized after treat-
ment [352]. It is conceivable that vIL-6 triggers expression of
IL-6 and release of the sIL-6R, which then stimulates disease
activity by the positive feedback loops described above.
IL-6 levels are elevated in the serum and lymph nodes of
HIV-positive patients with B-cell activation or B-cell lym-
phomas [353,354]. An increased release of sIL-6R was
found in HIV- and HTLV-1-infected patients [28,355], but
there is also an increased expression of the 80-kDa, mem-
brane-bound IL-6R on monocytes and B-cells from HIV-
positive patients [356]. IL-6 may protect HIV-envelope-
protein-expressing B-lymphocytes from lysis by cytotoxic
CD8+ T-cells, possibly by an anti-apoptotic effect of IL-6
[357]. Elevated HIV production has been observed after
stimulation with the proinflammatory cytokines IL-1, IL-18,
TNFa or IL-6 [358,359]. IL-6 participates in the reactiva-
tion of HIV replication from CD4+-T cells after cessation of
highly active anti-retroviral therapy (HAART) [358]. Some
HIV-infected patients suffer from herpesvirus-associated
immune restoration disease after the beginning of HAART
[360]. A distinct rise of bioactive IL-6/sIL-6R complexes
was observed that persisted for up to 4 years. The pathoge-
netic significance of this rise is unknown. However, appli-
cation of an anti-IL-6 antibody, BE-8, in patients at a late
stage of AIDS neither affected HIV load nor circulating cell
counts, but it normalized levels of acute-phase proteins
(CRP, fibrinogen), IgG and IgA, and improved the wasting
syndrome of AIDS [361].
9.3. Prostate carcinoma
IL-6 has been identified as a paracrine and autocrine
growth factor of human prostate cancer, one of the com-
monest malignancies in males [362]. Expression of the IL-
6R was observed in all investigated pathological tumour
specimens [363]. The androgen-sensitive LNCaP cell line
secretes large amounts of sIL-6R, whereas secretion of sIL-
6R in the androgen-insensitive DU145 and PC3 cell lines is
upregulated by dexamethasone [364]. IL-6 signalling in
prostate carcinoma cells involves activation of the growth
factor tyrosine kinase receptors ErbB2/neu and ErbB3 and
the ras/MAP-kinase pathway [365]. Furthermore, Etk, a
tyrosine kinase with a pleckstrin-homology domain, is
activated via a PI-3-kinase-dependent mechanism [366].
Etk is expressed in all prostate cancer cells and structurally
resembles Btk, a tyrosine kinase that is important for B-cell
activation and development. Importantly, IL-6 is a non-
steroidal, ligand-independent activator of the androgen
receptor and upregulates the diagnostic prostate specific
antigen [367]. In vitro, IL-6 and OSM confer resistance of
prostate carcinoma cells to etoposide and cisplatin, which
can be reversed by antisence oligonucleotides against gp130
or inhibitors of p21ras isoprenylation [368]. Recently, it was
shown that IL-6 and sIL-6R levels are dramatically elevated
in prostate cancer with bone metastasis, while preoperative
levels of IL-6/sIL-6R correlated with disease progression
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after surgery in localised prostate cancer, possibly indicating
occult metastasis at the time of surgery [369].
9.4. Breast cancer
A role of IL-6 in other malign tumours is less well
established. IL-6 has been reported to induce proliferation
of bladder carcinoma cells [370] and small cell lung cancer
cells [371]. IL-6 inhibits the growth of estrogen receptor
(ER)-positive, but not ER ( ), breast cancer cells [372]. ER
(+) breast cancer cells do not secrete IL-6, but express the
sIL-6R, while ER ( ) cells express the membrane-bound
IL-6R and secrete IL-6. The effects therefore do not seem to
arise from autocrine stimulation. sIL-6R isolated from urine
was found to enhance IL-6-dependent growth inhibition on
human breast cancer cells, although these cells expressed
ample amounts of IL-6R [373]. The sIL-6R in conditioned
medium from breast cancer cells was identified as the
alternatively spliced variant [27]. In a study on 75 patients,
expression of IL-6, IL-6R and gp130 in the microenviron-
ment of breast cancer indicated improved overall and dis-
ease-free survival as an independent prognostic factor [374].
The choice of primers used for RT-PCR, however, did not
allow to differentiate between soluble and membrane-bound
IL-6R. On the other hand, cytokines, including IL-6, released
from glial cells seemed to promote brain metastases origi-
nating from breast cancer [375]. Similarly, IL-6 increases
metastasis of ovarian cancer cells by effecting their migration
and attachment [376].
IL-6 promotes growth of cervical carcinoma cells by a
seemingly autocrine mechanism [377]. However, in several
human cervical carcinoma cell lines, the IL-6R was down-
regulated at the transcriptional level, causing low IL-6 re-
sponsiveness despite high IL-6 expression [378]. As a
consequence, expression of MCP-1 by carcinoma cells was
diminished which may constitute an immune escape mech-
anism for the tumour. IL-6/sIL-6R activates the human
papillomavirus type 18 long-term control region through
phosphorylation of STAT3, which could imply that STAT3
is important for oncogene activation in cervical carcinoma
[379].
9.5. Anti-tumour effects of IL-6
Low immunogenic B16 melanoma cells stably trans-
fected with Hyper-IL-6 were almost completely rejected
after subcutaneous injection into C57BL/6 mice [173,380].
The effect depended on GM-CSF activity and was sup-
pressed in mice transgenic for a GM-CSF receptor antag-
onist. A tumour vaccine against human melanoma, com-
posed of irradiated autologous melanoma cells mixed with
allogeneic melanoma cells overexpressing Hyper-IL-6,
appears to have anti-tumour activity in disseminated
advanced stage melanoma [381]. Apparently, an immune
response that includes CD8+-T-cells and NK-cells is trig-
gered. Hyper-IL-6 is also tested in expansion protocols of
dendritic cells with the aim to vaccinate against tumours
[175,382].
10. Treatment options
A neutralizing antibody against the IL-6R is presently
tested for clinical activity. This antibody has already shown
positive effects in animal models of RA, MM, autoimmune
kidney disease and Crohn’s disease [10,124,162]. Anti-IL-
6R antibodies have shown impressive efficacy in animal
models. Clinical phase I and II studies with the neutralizing
anti-IL-6R antibody MRA are now underway [125]. Experi-
ments in mice showed that at least three different antibodies
directed against three different epitopes are necessary for
effective clearance of the sIL-6R [383]. A different thera-
peutic approach exists in the gp130–Fc fusion protein that
specifically inhibits biological effects and pathology depend-
ing on the soluble receptor [44]. In vitro and in vivo, gp130–
Fc has proven effective and specific inhibition of activities
mediated via the sIL-6R, whereas effects mediated via the
membrane-bound IL-6R remain unaffected [10,44]. It there-
fore appears a promising therapeutic agent for the treatment
of human diseases in which the sIL-6R plays a pivotal role.
11. Open questions
The release of the sIL-6R is an important step in the
pathogenesis of a diversity of diseases and in many instan-
ces where IL-6 is considered as an important pathogenic
factor; this view might need to be widened to include the
sIL-6R. It will therefore be necessary to investigate the
mechanisms controlling the shedding of the IL-6R in more
detail. On the other hand, the sIL-6R can also be released by
alternative splicing, so that the regulatory elements of this
pathway need to be studied. Assays are now available that
exploit the additional amino acids at the COOH-terminus of
the alternatively spliced sIL-6R to discern between sIL-6R
generated by shedding or alternative splicing. One major
question to be solved is whether the two variants of the sIL-
6R also serve different functions.
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